US Patent 9,155,716 landscape: scope, claim coverage, and competitive blocking points for once-daily bimatoprost with benzalkonium chloride

US Patent 9,155,716 protects a glaucoma/ocular hypertension treatment method tied to a specific fixed combination and dosing regimen: once-daily intraocular administration of a “first composition” containing ~0.01% w/v bimatoprost plus ~0.02% w/v benzalkonium chloride (BAK), positioned as clinically better for ocular surface tolerability than a specified comparator “second composition” of 0.03% w/v bimatoprost plus 0.005% w/v BAK. The independent claim is a method claim anchored to (i) exact concentration ranges via “about” and (ii) comparative clinical outcomes (IOP lowering and tolerability), with dependent claims further tightening pH and formulation components.

What matters commercially is that the asserted hook is not simply “lower bimatoprost exposure” or “change preservative,” but a particular preservative concentration combined with a lower bimatoprost strength under a once-daily dosing schedule, with performance framing (less punctate keratitis, less hyperemia, fewer AEs).

What is US Patent 9,155,716 claiming: method-of-use for lowering intraocular pressure with a specific bimatoprost/BAK composition?

Claim 1 is the core scope. It requires all elements:

Patient population: a person with glaucoma or ocular hypertension.
Route/site: “administering … to an eye.”
Dosing frequency: once daily.
First composition concentration:
- bimatoprost ~0.01% w/v
- BAK ~0.02% w/v
Method performance:
- lowers intraocular pressure as effectively as the comparator regimen.
Tolerability improvement:
- “improved ocular surface tolerability” vs the comparator composition.
Comparator composition (for the claim’s performance framing):
- 0.03% bimatoprost
- 0.005% BAK
- once daily.

Claim construction impact (practical)
Because the independent claim is a method claim, liability risk attaches to practicing the claimed regimen, not manufacturing alone. However, the regimen is defined by the composition parameters and the claimed comparative outcomes. For a generic or alternative to avoid infringement, it must typically change at least one required element: bimatoprost strength, BAK level, dosing frequency, or the pH/formulation features that are later limited in dependent claims.

How broad is the “about 0.01% bimatoprost and about 0.02% BAK” scope?

The claim uses “about,” so real-world scope depends on how “about” is construed in litigation (not provided in the claim text). Still, the claim’s numerics are tight enough that design-around often targets one lever:

Bimatoprost strength: moving away from ~0.01% w/v (e.g., higher strength such as 0.02% or returning to 0.03%) can break the first-composition requirement.
BAK concentration: moving away from ~0.02% w/v can break the first-composition requirement even if bimatoprost remains ~0.01%.
Comparator anchoring: the claim’s effectiveness and tolerability comparisons are to a specific comparator. If an accused product uses a different comparator in a way that changes the trial endpoints, infringement arguments shift toward whether the claimed method “results” in the recited comparative benefits.

In practice, the strongest infringement theories are where an accused product uses the same or near-identical concentrations and is labeled or marketed with the same clinical positioning: IOP-lowering plus ocular surface tolerability improvements.

What do dependent claims 2–4 cover: pH limitations at about 7.3?

Claim 2 depends from claim 1 and requires:

first composition pH ~7.3.

Claims 3–4 add tighter composition and pH coverage:

Claim 3: explicitly recites 0.01% bimatoprost + 0.02% BAK (consistent with claim 1).
Claim 4: requires pH ~7.3.

Scope impact
Dependent claims add formulation specificity. Even if a competitor matches concentrations but uses a different pH target, claim 1 can still be asserted; claims 2 and 4 would be harder to reach. Claim drafting suggests the patent holder is treating pH ~7.3 as part of the tolerability profile (or at least part of the exemplified regimen).

What are the “improved tolerability” outcome limitations: punctate keratitis and hyperemia claims 5–8?

Dependent claims convert clinical endpoints into claim limitations. These are important because they create two infringement pathways:

If an accused product produces similar clinical outcomes, enforcement is strengthened.
If an accused product changes formulation parameters that affect ocular surface health, infringement risk for these dependent claims declines.

Claim 5: less punctate keratitis vs the comparator.

Claims 6–8: less hyperemia over a 12-month period, with granularity:

Claim 6: less hyperemia over 12 months.
Claim 7: less macroscopic hyperemia.
Claim 8: less moderate/severe hyperemia.

Scope impact
These claims are tied to relative performance “as compared to” the comparator composition. If the accused product is not used under the same clinical regimen or does not demonstrate the same comparative reductions, the factual record becomes central. For litigation, this means the patent’s practical enforceability depends heavily on clinical study comparators, measurement standards, and duration.

What formulation component limitations exist: claims 9–12 and their likely design-around leverage?

Claims 9–12 add specific excipient and buffer systems that can narrow dependent claim coverage.

Claim 9 adds:

sodium phosphate heptahydrate
citric acid monohydrate
water.

Claim 10 further specifies a broader set:

sodium phosphate heptahydrate
citric acid monohydrate
water
sodium chloride
pH adjustment using hydrochloric acid and sodium hydroxide.

Claim 11: less adverse events compared to the once daily comparator (overall AEs, ocular AEs, treatment-related AEs, ocular treatment-related AEs).

Claim 12: adds numerical levels:

about 0.26% w/v dibasic sodium phosphate heptahydrate
about 0.8% w/v sodium chloride.

Scope impact
These excipient claims give competitors more obvious “escape routes” at the dependent level by changing buffer salt form, buffer ratios, or ionic strength. But they do not eliminate infringement risk under claim 1 unless the excipient constraints are needed to practice the “first composition” as interpreted by the court. Since claim 1 does not mention excipients, claim 1 is the main enforcement lever; claims 9–12 create additional hooks if an accused product matches the full formulation.

What patents protect bimatoprost ocular hypotensive methods with altered preservative strength and tolerability claims?

Without the patent family metadata (priority, assignees, and prosecution history) or the full claim set beyond the excerpt, a complete US patent landscaping across the entire estate cannot be produced with hard accuracy. The scope provided indicates this patent is directed to a narrow parameter space: bimatoprost concentration lowered to ~0.01% paired with a higher BAK level ~0.02%, plus a tolerability profile established in clinical comparisons to a bimatoprost 0.03%/BAK 0.005% comparator.

Business-ready takeaway on the patent landscape logic:

Patents in this space typically cluster by:
- Active concentration (bimatoprost strength).
- Preservative system (BAK level and type).
- pH and buffer (ocular surface tolerability tuning).
- Method-of-use (once-daily dosing; patient population; comparative tolerability outcomes).
- Manufacturing or composition-by-process (less likely to dominate here because claim 1 is method-based and defined by concentrations).
Because this patent is a method of lowering IOP tied to tolerability outcomes, the most relevant competitive patents are those that either:
- protect the same regimen, or
- protect alternative regimens designed to trade off IOP efficacy versus ocular surface parameters.

Which generic entry risks exist for products that could target the same low-dose bimatoprost/BAK regimen?

The practical infringement and ANDA/505(b)(2) risk depends on whether an applicant seeks to copy the claimed concentrations and regimen.

Highest risk scenario

An applicant uses a product with ~0.01% bimatoprost and ~0.02% BAK, dosed once daily, and achieves labeling and/or clinical positioning consistent with “as effective IOP lowering” and “improved ocular surface tolerability” relative to a higher-bimatoprost/lower-BAK comparator.

Lower risk scenario (design-around)
Any of the following often reduces risk materially:

Shift bimatoprost concentration away from the claimed “about 0.01%.”
Shift BAK away from “about 0.02%.”
Change pH away from ~7.3 (dependent claim narrowing).
Reformulate buffer and excipient system to avoid dependent claims 9–12.

Because the claims contain multiple comparative outcome limitations (punctate keratitis, hyperemia, AEs), applicants can also mitigate risk by choosing study endpoints or comparators that do not align with the “as compared to the once daily second composition” framing, though this does not eliminate claim-construction and proof hurdles.

How does US 9,155,716 compare with common bimatoprost strengths and preservative strategies?

Based strictly on the excerpt, US 9,155,716 contrasts two compositions:

First composition (claimed): 0.01% bimatoprost + 0.02% BAK.
Second composition (comparator): 0.03% bimatoprost + 0.005% BAK.

This is a non-standard trade: it pairs lower prostaglandin strength with a higher BAK than the comparator, while claiming improved ocular surface tolerability. That structure can inform competitive interpretation:

Competitors relying on the well-known bimatoprost/BAK positioning of the higher-strength comparator face the most direct comparison risk.
Competitors that reduce BAK while keeping higher bimatoprost may not match the claimed “first composition,” but their ocular tolerability improvements will be tested against the patent’s comparative logic.

What is the enforceability profile of claim 1 vs claims 2–12?

Claim 1 is broadest and strongest for enforcement because it only requires:

the concentration pair (bimatoprost and BAK),
once-daily administration,
and a comparative performance/tolerability result.

Claims 2–4 (pH ~7.3) narrow dependent coverage but add another formulation lever.

Claims 5–8 (clinical tolerability metrics, including 12-month duration) narrow to demonstrable outcomes. These can be potent if the accused product’s trial data aligns with the claimed measurements and timepoints.

Claims 9–12 (buffer/excipient details) are the most design-around-friendly, since excipients and salt forms can be modified while still maintaining basic ocular hypotensive performance.

Claim 11 (adverse events reduction) also depends on clinical data and comparative framing.

Key takeaways on scope and practical IP strategy

US 9,155,716 centers on a once-daily method of lowering IOP using a very specific bimatoprost/BAK concentration pairing: ~0.01% bimatoprost with ~0.02% BAK.
The patent is built to enforce through comparative ocular surface outcomes (punctate keratitis, hyperemia, AEs) versus a specified bimatoprost 0.03%/BAK 0.005% comparator regimen.
Dependent claims tighten scope with pH ~7.3 and specific buffering/excipient systems (sodium phosphate heptahydrate, citric acid monohydrate, NaCl, acid/base for pH, and specific dibasic sodium phosphate and NaCl concentrations).
For a competitor, the most direct design-around lever is shifting either bimatoprost concentration or BAK concentration. Dependent claim avoidance is also achievable by altering pH and buffer/excipient systems.

FAQs

1) Does US 9,155,716 cover manufacturing of the formulation or only administration?
It is written as a method of lowering intraocular pressure via administering a first composition once daily to an eye, so enforcement targets practicing the regimen; manufacturing-only arguments are not the primary fit for claim 1.

2) If a product matches bimatoprost ~0.01% and BAK ~0.02% but uses a different pH, is it still covered?
Claim 1 does not recite pH, so mismatched pH primarily affects dependent claims 2 and 4 rather than eliminating claim 1 risk.

3) How important is the 12-month duration in US 9,155,716?
It is explicitly required in claims 6–8 for the hyperemia comparisons, making those dependent claims more data- and duration-specific.

4) What is the biggest design-around for biosurface tolerability patents like this?
Avoiding the exact concentration pairing is the highest-impact approach. Changing pH/buffer and excipient composition helps for dependent claims but may not defeat claim 1.

5) Can a challenger argue non-infringement by disputing clinical outcomes?
For dependent claims with tolerability and adverse-event limitations, clinical outcome proof is central. Claim 1 includes comparative effectiveness and tolerability language, so factual record will matter.

References

US Patent 9,155,716, claims as provided in the prompt (method of lowering intraocular pressure using once-daily administration of ~0.01% w/v bimatoprost and ~0.02% w/v benzalkonium chloride with comparative tolerability vs 0.03% bimatoprost and 0.005% w/v benzalkonium chloride).

Title:	Enhanced bimatoprost ophthalmic solution
Abstract:	A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
Inventor(s):	Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
Assignee:	Allergan Inc
Application Number:	US13/826,047
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,155,716
Patent Claim Types: see list of patent claims	Use; Composition;
Patent landscape, scope, and claims:	US Patent 9,155,716 landscape: scope, claim coverage, and competitive blocking points for once-daily bimatoprost with benzalkonium chloride US Patent 9,155,716 protects a glaucoma/ocular hypertension treatment method tied to a specific fixed combination and dosing regimen: once-daily intraocular administration of a “first composition” containing ~0.01% w/v bimatoprost plus ~0.02% w/v benzalkonium chloride (BAK), positioned as clinically better for ocular surface tolerability than a specified comparator “second composition” of 0.03% w/v bimatoprost plus 0.005% w/v BAK. The independent claim is a method claim anchored to (i) exact concentration ranges via “about” and (ii) comparative clinical outcomes (IOP lowering and tolerability), with dependent claims further tightening pH and formulation components. What matters commercially is that the asserted hook is not simply “lower bimatoprost exposure” or “change preservative,” but a particular preservative concentration combined with a lower bimatoprost strength under a once-daily dosing schedule, with performance framing (less punctate keratitis, less hyperemia, fewer AEs). What is US Patent 9,155,716 claiming: method-of-use for lowering intraocular pressure with a specific bimatoprost/BAK composition? Claim 1 is the core scope. It requires all elements: Patient population: a person with glaucoma or ocular hypertension. Route/site: “administering … to an eye.” Dosing frequency: once daily. First composition concentration: bimatoprost ~0.01% w/v BAK ~0.02% w/v Method performance: lowers intraocular pressure as effectively as the comparator regimen. Tolerability improvement: “improved ocular surface tolerability” vs the comparator composition. Comparator composition (for the claim’s performance framing): 0.03% bimatoprost 0.005% BAK once daily. Claim construction impact (practical) Because the independent claim is a method claim, liability risk attaches to practicing the claimed regimen, not manufacturing alone. However, the regimen is defined by the composition parameters and the claimed comparative outcomes. For a generic or alternative to avoid infringement, it must typically change at least one required element: bimatoprost strength, BAK level, dosing frequency, or the pH/formulation features that are later limited in dependent claims. How broad is the “about 0.01% bimatoprost and about 0.02% BAK” scope? The claim uses “about,” so real-world scope depends on how “about” is construed in litigation (not provided in the claim text). Still, the claim’s numerics are tight enough that design-around often targets one lever: Bimatoprost strength: moving away from ~0.01% w/v (e.g., higher strength such as 0.02% or returning to 0.03%) can break the first-composition requirement. BAK concentration: moving away from ~0.02% w/v can break the first-composition requirement even if bimatoprost remains ~0.01%. Comparator anchoring: the claim’s effectiveness and tolerability comparisons are to a specific comparator. If an accused product uses a different comparator in a way that changes the trial endpoints, infringement arguments shift toward whether the claimed method “results” in the recited comparative benefits. In practice, the strongest infringement theories are where an accused product uses the same or near-identical concentrations and is labeled or marketed with the same clinical positioning: IOP-lowering plus ocular surface tolerability improvements. What do dependent claims 2–4 cover: pH limitations at about 7.3? Claim 2 depends from claim 1 and requires: first composition pH ~7.3. Claims 3–4 add tighter composition and pH coverage: Claim 3: explicitly recites 0.01% bimatoprost + 0.02% BAK (consistent with claim 1). Claim 4: requires pH ~7.3. Scope impact Dependent claims add formulation specificity. Even if a competitor matches concentrations but uses a different pH target, claim 1 can still be asserted; claims 2 and 4 would be harder to reach. Claim drafting suggests the patent holder is treating pH ~7.3 as part of the tolerability profile (or at least part of the exemplified regimen). What are the “improved tolerability” outcome limitations: punctate keratitis and hyperemia claims 5–8? Dependent claims convert clinical endpoints into claim limitations. These are important because they create two infringement pathways: If an accused product produces similar clinical outcomes, enforcement is strengthened. If an accused product changes formulation parameters that affect ocular surface health, infringement risk for these dependent claims declines. Claim 5: less punctate keratitis vs the comparator. Claims 6–8: less hyperemia over a 12-month period, with granularity: Claim 6: less hyperemia over 12 months. Claim 7: less macroscopic hyperemia. Claim 8: less moderate/severe hyperemia. Scope impact These claims are tied to relative performance “as compared to” the comparator composition. If the accused product is not used under the same clinical regimen or does not demonstrate the same comparative reductions, the factual record becomes central. For litigation, this means the patent’s practical enforceability depends heavily on clinical study comparators, measurement standards, and duration. What formulation component limitations exist: claims 9–12 and their likely design-around leverage? Claims 9–12 add specific excipient and buffer systems that can narrow dependent claim coverage. Claim 9 adds: sodium phosphate heptahydrate citric acid monohydrate water. Claim 10 further specifies a broader set: sodium phosphate heptahydrate citric acid monohydrate water sodium chloride pH adjustment using hydrochloric acid and sodium hydroxide. Claim 11: less adverse events compared to the once daily comparator (overall AEs, ocular AEs, treatment-related AEs, ocular treatment-related AEs). Claim 12: adds numerical levels: about 0.26% w/v dibasic sodium phosphate heptahydrate about 0.8% w/v sodium chloride. Scope impact These excipient claims give competitors more obvious “escape routes” at the dependent level by changing buffer salt form, buffer ratios, or ionic strength. But they do not eliminate infringement risk under claim 1 unless the excipient constraints are needed to practice the “first composition” as interpreted by the court. Since claim 1 does not mention excipients, claim 1 is the main enforcement lever; claims 9–12 create additional hooks if an accused product matches the full formulation. What patents protect bimatoprost ocular hypotensive methods with altered preservative strength and tolerability claims? Without the patent family metadata (priority, assignees, and prosecution history) or the full claim set beyond the excerpt, a complete US patent landscaping across the entire estate cannot be produced with hard accuracy. The scope provided indicates this patent is directed to a narrow parameter space: bimatoprost concentration lowered to ~0.01% paired with a higher BAK level ~0.02%, plus a tolerability profile established in clinical comparisons to a bimatoprost 0.03%/BAK 0.005% comparator. Business-ready takeaway on the patent landscape logic: Patents in this space typically cluster by: Active concentration (bimatoprost strength). Preservative system (BAK level and type). pH and buffer (ocular surface tolerability tuning). Method-of-use (once-daily dosing; patient population; comparative tolerability outcomes). Manufacturing or composition-by-process (less likely to dominate here because claim 1 is method-based and defined by concentrations). Because this patent is a method of lowering IOP tied to tolerability outcomes, the most relevant competitive patents are those that either: protect the same regimen, or protect alternative regimens designed to trade off IOP efficacy versus ocular surface parameters. Which generic entry risks exist for products that could target the same low-dose bimatoprost/BAK regimen? The practical infringement and ANDA/505(b)(2) risk depends on whether an applicant seeks to copy the claimed concentrations and regimen. Highest risk scenario An applicant uses a product with ~0.01% bimatoprost and ~0.02% BAK, dosed once daily, and achieves labeling and/or clinical positioning consistent with “as effective IOP lowering” and “improved ocular surface tolerability” relative to a higher-bimatoprost/lower-BAK comparator. Lower risk scenario (design-around) Any of the following often reduces risk materially: Shift bimatoprost concentration away from the claimed “about 0.01%.” Shift BAK away from “about 0.02%.” Change pH away from ~7.3 (dependent claim narrowing). Reformulate buffer and excipient system to avoid dependent claims 9–12. Because the claims contain multiple comparative outcome limitations (punctate keratitis, hyperemia, AEs), applicants can also mitigate risk by choosing study endpoints or comparators that do not align with the “as compared to the once daily second composition” framing, though this does not eliminate claim-construction and proof hurdles. How does US 9,155,716 compare with common bimatoprost strengths and preservative strategies? Based strictly on the excerpt, US 9,155,716 contrasts two compositions: First composition (claimed): 0.01% bimatoprost + 0.02% BAK. Second composition (comparator): 0.03% bimatoprost + 0.005% BAK. This is a non-standard trade: it pairs lower prostaglandin strength with a higher BAK than the comparator, while claiming improved ocular surface tolerability. That structure can inform competitive interpretation: Competitors relying on the well-known bimatoprost/BAK positioning of the higher-strength comparator face the most direct comparison risk. Competitors that reduce BAK while keeping higher bimatoprost may not match the claimed “first composition,” but their ocular tolerability improvements will be tested against the patent’s comparative logic. What is the enforceability profile of claim 1 vs claims 2–12? Claim 1 is broadest and strongest for enforcement because it only requires: the concentration pair (bimatoprost and BAK), once-daily administration, and a comparative performance/tolerability result. Claims 2–4 (pH ~7.3) narrow dependent coverage but add another formulation lever. Claims 5–8 (clinical tolerability metrics, including 12-month duration) narrow to demonstrable outcomes. These can be potent if the accused product’s trial data aligns with the claimed measurements and timepoints. Claims 9–12 (buffer/excipient details) are the most design-around-friendly, since excipients and salt forms can be modified while still maintaining basic ocular hypotensive performance. Claim 11 (adverse events reduction) also depends on clinical data and comparative framing. Key takeaways on scope and practical IP strategy US 9,155,716 centers on a once-daily method of lowering IOP using a very specific bimatoprost/BAK concentration pairing: ~0.01% bimatoprost with ~0.02% BAK. The patent is built to enforce through comparative ocular surface outcomes (punctate keratitis, hyperemia, AEs) versus a specified bimatoprost 0.03%/BAK 0.005% comparator regimen. Dependent claims tighten scope with pH ~7.3 and specific buffering/excipient systems (sodium phosphate heptahydrate, citric acid monohydrate, NaCl, acid/base for pH, and specific dibasic sodium phosphate and NaCl concentrations). For a competitor, the most direct design-around lever is shifting either bimatoprost concentration or BAK concentration. Dependent claim avoidance is also achievable by altering pH and buffer/excipient systems. FAQs 1) Does US 9,155,716 cover manufacturing of the formulation or only administration? It is written as a method of lowering intraocular pressure via administering a first composition once daily to an eye, so enforcement targets practicing the regimen; manufacturing-only arguments are not the primary fit for claim 1. 2) If a product matches bimatoprost ~0.01% and BAK ~0.02% but uses a different pH, is it still covered? Claim 1 does not recite pH, so mismatched pH primarily affects dependent claims 2 and 4 rather than eliminating claim 1 risk. 3) How important is the 12-month duration in US 9,155,716? It is explicitly required in claims 6–8 for the hyperemia comparisons, making those dependent claims more data- and duration-specific. 4) What is the biggest design-around for biosurface tolerability patents like this? Avoiding the exact concentration pairing is the highest-impact approach. Changing pH/buffer and excipient composition helps for dependent claims but may not defeat claim 1. 5) Can a challenger argue non-infringement by disputing clinical outcomes? For dependent claims with tolerability and adverse-event limitations, clinical outcome proof is central. Claim 1 includes comparative effectiveness and tolerability language, so factual record will matter. References US Patent 9,155,716, claims as provided in the prompt (method of lowering intraocular pressure using once-daily administration of ~0.01% w/v bimatoprost and ~0.02% w/v benzalkonium chloride with comparative tolerability vs 0.03% bimatoprost and 0.005% w/v benzalkonium chloride). More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	055050	⤷ Start Trial
Austria	E431152	⤷ Start Trial
Australia	2006227757	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,155,716

Summary for Patent: 9,155,716